Skip Navigation

European Heart Journal 1989 10(Supplement E):66-72; doi:10.1093/eurheartj/10.suppl_E.66
Copyright © 1989 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Podrid, P. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Podrid, P. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1989 The European Society of Cardiology

Aggravation of arrhythmia: A complication of antiarrhythmic drug therapy

P. J. Podrid

The Arrhythmia Group, Boston University School of Medicine, University Hospital Boston, Massachusetts, U.S.A.

Address for correspondence: Philip J. Podrid M.D., Boston University School of Medicine, Section of Cardiology, University Hospital, Boston, MA 02118, U.S.A

Aggravation of arrhythmia is a complication of antiarrhythmic drug therapy that is not uncommon. It may represent a worsening of an existing arrhythmia or a new arrhythmia not previously experienced by the patient. When non-invasive methods are used to evaluate drug effects, the overall incidence of aggravation is 9% while with electrophysiologic testing, it is 18%. While aggravation of arrhythmia may occur when the blood level of the drug is in the toxic range, most often this complication is observed when blood levels are in the defined therapeutic range. It is not associated with drug dose, baseline ECG intervals, changes in these intervals during therapy, the nature of the heart disease or other clinical parameters. However, it is more common in patients with a history of sustained ventricular tachycardia or ventricular fibrillation and in those with reduced left ventricular function and a history of congestive heart failure. Aggravation with one drug does not predict this complication with another agent, even if both are in the same subclass. Worsening of arrhythmia may often be precipitated by exercise testing, even when arrhythmia is suppressed on ambulatory monitoring. The frequency, unpredictability and seriousness of this side-effect demands the cautious use of antiarrhythmic dr

Key Words: Aggravation of arrhythmia • antiarrhythmic drugs • toxicity


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JAMAHome page
B. O'Kelly, W. S. Browner, B. Massie, J. Tubau, L. Ngo, D. T. Mangano, the Study of Perioperative Ischemia Research Group, D. T. Mangano, M. J. London, W. S. Browner, et al.
Ventricular Arrhythmias in Patients Undergoing Noncardiac Surgery
JAMA, July 8, 1992; 268(2): 217 - 221.
[Abstract] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.